Lze zlepšit komplianci pacientů k dlouhodobé terapii statiny?

SOŠKA, Vladimír a Ondřej KYSELÁK. Lze zlepšit komplianci pacientů k dlouhodobé terapii statiny? Vnitřní lékařství. Praha: Česká lékařská společnost J.E. Purkyně, 2017, roč. 63, č. 10, s. 663-666. ISSN 0042-773X.

Základní údaje

• Originální název: Lze zlepšit komplianci pacientů k dlouhodobé terapii statiny?
• Název anglicky: Is it possible to improve long-term compliance of patients to statin therapy?
• Autoři: SOŠKA, Vladimír (203 Česká republika, garant, domácí) a Ondřej KYSELÁK (203 Česká republika).
• Vydání: Vnitřní lékařství, Praha, Česká lékařská společnost J.E. Purkyně, 2017, 0042-773X.

Další údaje

• Originální jazyk: čeština
• Typ výsledku: Článek v odborném periodiku
• Obor: 30200 3.2 Clinical medicine
• Stát vydavatele: Česká republika
• Utajení: není předmětem státního či obchodního tajemství
• Kód RIV: RIV/00216224:14110/17:00098601
• Organizační jednotka: Lékařská fakulta
• Klíčová slova anglicky: Compliance; Creatinkinase; Diabetes mellitus; Ldl-cholesterol; Statins
• Štítky: EL OK
• Příznaky: Mezinárodní význam, Recenzováno

Anotace

Statins are key drugs for patients in secondary prevention of cardiovascular disease, as well as for primary prevention patients at high or very high risk of fatal cardiovascular events. However, long-term compliance of patients to statin therapy is relatively low, decreasing with the time of statin use; moreover a significant proportion of patients stop statins medication over the course of several years. To the early termination of statin treatment often contributes apprehension of the occurence of statin's side effects (i.g. increased creatine kinase in the blood and muscle problems), although these symptoms are usually not causally related to statin therapy. To the low compliance may also contribute administration of statins in the evening hours, as well as the fear of developing diabetes or drug interactions. The above issues are discussed in the text of this article.

Anotace anglicky

Statins are key drugs for patients in secondary prevention of cardiovascular disease, as well as for primary prevention patients at high or very high risk of fatal cardiovascular events. However, long-term compliance of patients to statin therapy is relatively low, decreasing with the time of statin use; moreover a significant proportion of patients stop statins medication over the course of several years. To the early termination of statin treatment often contributes apprehension of the occurence of statin's side effects (i.g. increased creatine kinase in the blood and muscle problems), although these symptoms are usually not causally related to statin therapy. To the low compliance may also contribute administration of statins in the evening hours, as well as the fear of developing diabetes or drug interactions. The above issues are discussed in the text of this article.